fda regulations on tirzepatide Is a Stimulant? Mechanism and Safety Profile FDA says shortage of GLP-1

The data doesnt specify the causes of death in every case, but it aligns with known risks such as gastrointestinal issues, pancreatitis, and, in rare instances, kidney or cardiovascular complications

In case you have an allergic reaction, please discontinue use and consult your doctor immediately

To meet the prescribing criteria, patients generally need a BMI above 27 with a weight-related comorbidity, such as diabetes, sleep apnea or high blood pressureor a BMI above 30 with or without a cormorbidity

Reduced anxiety and depression, which are common comorbidities of obesity, may contribute to enhanced libido and sexual satisfaction

A nutrient-dense diet and regular exercise are essential when on a GLP-1 to prevent long-term damage from malnutrition and rapid weight loss